Cogent Biosciences (COGT) Gains from Sales and Divestitures (2020 - 2025)
Cogent Biosciences (COGT) recorded quarterly Gains from Sales and Divestitures of $80000.0 in Q4 2025, little changed quarter-over-quarter from $80400.0 in Q4 2020.
Cogent Biosciences (COGT) Gains from Sales and Divestitures (2020 - 2025) Analysis & Trends
Cogent Biosciences' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $80000.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $80000.0; the TTM figure through Dec 2025 stood at $80000.0 (changed N/A YoY), while the FY2025 annual figure was $80000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $80000.0 for Q4 2025 at Cogent Biosciences, roughly flat from $80400.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $80000.0 in Q4 2025 to a low of $80000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Cogent Biosciences | 5.09 Bn | 4.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80,000.00 |
| Dec 31, 2025 | 80,000.00 |
| Dec 31, 2020 | 80,400.00 |
| Dec 31, 2020 | 80,400.00 |